Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYSNYSE / NASDAQHealthcareMid cap

$308.89-$6.93 (-2.2%)

Last close · Data as of Nov 20, 2026

Market cap
$9.1B
P/E
44.3x
EV / EBITDA
51.2x
Revenue
$389.1M
Net margin
52.6%
ROCE
13.1%

+51.2% over the last year

Krystal Biotech, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-5.1%
3M
-8.3%
6M
+2.3%
1Y
+51.2%
5Y
Hidden
  • This period includes a one-day price step on 29 Nov 2021 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$6.93 (-2.2%) from $316 to $309 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in KRYS, bought on each weekday since 2021.

News & filings

What Krystal Biotech filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 41.5% against a peer median of 5.8%.

Concerns (1)

  • The P/E of 44.3 is 103% above the peer median of 21.8.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Read moreShow less

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Sector
Healthcare
Shares outstanding
28.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$9.1B
P/E
44.3x
P/B
7.4x
EV / EBITDA
51.2x
EV / Sales
22.1x
P/S
23.3x
52-week high
$378.15
52-week low
$204.23

Profitability

Operating margin
41.5%
Net margin
52.6%
EBITDA margin
43.1%
ROE
16.8%
ROCE
13.1%
ROA
15.4%
Asset turnover
0.29

Growth

Revenue
$389.1M
Revenue growth, 1Y
33.9%
Net profit growth, 1Y
129.7%
Free cash flow
$188.9M

Solvency

Current ratio
9.95
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.98
Cash / Market cap
5.5%

Where the revenue went

Of every $100 of FY2025 revenue, $53 was left as net income.

Krystal Biotech, Inc. income statement flow, FY2025
Krystal Biotech, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$23.1M
RevenueGross profit$366.1M
Gross profitResearch and development$58.0M
Gross profitSelling, general and administrative$146.7M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$161.3M
Operating incomePretax income$161.3M
Interest and other incomePretax income$28.2M
Pretax incomeNet income$189.5M
Tax benefit and otherNet income$15.4M

Revenue and net profit

Revenue grew 33.9% in FY2025; net profit is the dashed line.

Krystal Biotech, Inc. revenue and net profit by fiscal year
Krystal Biotech, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$140.0M
FY2023$50.7M$10.9M
FY2024$290.5M$89.2M
FY2025$389.1M$204.8M

Cash flows

FY2025: $200.9M from operations, $188.9M free after investment (dashed).

Krystal Biotech, Inc. operating and free cash flow by fiscal year
Krystal Biotech, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$100.6M-$153.5M
FY2023-$88.8M-$100.6M
FY2024$123.4M$119.2M
FY2025$200.9M$188.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$389.1M+33.9%1Y
EBITDA
$167.8M+52.6%1Y
Net profit
$204.8M+129.7%1Y
Cash from operations
$200.9M+62.7%1Y
Free cash flow
$188.9M+58.5%1Y
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$389.1M$167.8M$204.8M$188.9M16.8%+33.9%+129.7%

Monthly returns

Month-by-month returns of KRYS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.3B
Liabilities$114.2M
Equity$1.2B
Paid-in capital$1.2B
Retained earnings$24.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; KRYS highlighted.

P/E against peers

KRYS trades at 44.3x earnings against a peer median of 21.8x (a 103% premium).

Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc., Glaukos Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Krystal Biotech, Inc.KRYSthis companyP/E ↑ premium$9.1B44.3x7.4x16.8%51.2x
Molina Healthcare, Inc.MOH$10.0B21.3x2.5x11.6%—
Baxter International Inc.BAX$10.0B-10.4x1.6x-15.6%23.2x
Charles River Laboratories International, Inc.CRL$8.9B—2.8x-4.6%27.5x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Peer median—21.8x3.4x7.7%23.2x

Year-to-date ROI

KRYS since 1 January, against earlier years.

Historical volatility

KRYS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Krystal Biotech, Inc. operating margin by fiscal year
Krystal Biotech, Inc. operating margin by fiscal year
DateOperating margin
FY2023-191.6%
FY202435.5%
FY202541.4%
LineFY2025
Cost of revenueCost Of Revenue$23.1M
Gross profitGross Profit$366.1M
Operating expensesOperating Expense$204.8M
Research and developmentResearch And Development$58.0M
Total expensesTotal Expenses$227.8M
Pretax incomePretax Income$189.5M

Learn while you research

Academy chapters picked for Krystal Biotech, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 44.3, learn when high multiples are justified.6 min read
  3. 03 Growth Investing34% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →